美第奇新星生物技术宣布,其评估MN-166(Ibudilast)用于治疗肌萎缩侧索硬化症患者的Seanobi研究扩展性用药项目,已成功达成患者招募的关键里程碑。这一进展标志着该药物在面向特定患者群体的可及性探索方面迈出了重要一步。
美第奇新星生物技术宣布,其评估MN-166(Ibudilast)用于治疗肌萎缩侧索硬化症患者的Seanobi研究扩展性用药项目,已成功达成患者招募的关键里程碑。这一进展标志着该药物在面向特定患者群体的可及性探索方面迈出了重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.